Active Biotech cancer, autoimmune news
Active Biotech said in its 2011 financial statement that it plans to reduce headcount by up to 25 (32%) to about 55 following a comprehensive overview of the organization. The company said its partners will increasingly handle projects as they move along in development. The company will focus on the Phase III trial of tasquinimod ( TASQ) to treat metastatic castration-resistant prostate cancer (CRPC), as well as the development of its project to develop compounds that inhibit S100 calcium binding protein A9 ( S100A9; calgranulin B; MRP14) to treat cancer indications. The company said it plans to select a product candidate from the project in 2013 or 2014. Active Biotech said the restructuring is expected to save about SEK10-12 million ($1.5-1.8 million) annually beginning in 2013. ...